Genocea Biosciences (NASDAQ:GNCA) : The consensus price target for Genocea Biosciences (NASDAQ:GNCA) is $18.8 for the short term with a standard deviation of $12.22. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $40, however, the pessimist price target for the company is $9.
Other Equity analysts have also commented on the company shares. UBS initiates coverage on Genocea Biosciences (NASDAQ:GNCA) In a research note issued to the investors, the brokerage major announces price-target of $15 per share.The shares have been rated Buy. The rating by the firm was issued on December 17, 2015.
Genocea Biosciences (NASDAQ:GNCA): stock turned positive on Thursday. Though the stock opened at $3.78, the bulls momentum made the stock top out at $4.89 level for the day. The stock recorded a low of $3.75 and closed the trading day at $4.67, in the green by 26.56%. The total traded volume for the day was 3,030,169. The stock had closed at $3.69 in the previous days trading.
The company shares have dropped -70.41% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $16.18 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $4.01 and the 200 Day Moving Average price is recorded at $4.51. On the companys insider trading activities, Poole Jonathan, CFO of Genocea Biosciences, Inc., executed a transaction worth $15,520 on May 9, 2016. A total of 4,000 shares were purchased at an average price of $3.88. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies to address diseases with unmet needs. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria. It also creates a library of every protein in the proteome of the pathogen of interest. It uses ATLAS as a throughput engine to screen human T cells to identify relevant T cell vaccine antigens.